Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts

被引:3
作者
Elghazaly, Hesham [1 ]
Mottet, Nicolas [2 ]
Garcia, Jorge [3 ]
Oudard, Stephane [4 ]
Roach, Mack [5 ]
Abbou, Claude [6 ]
Merseburger, Axel [7 ]
Emara, Amr [8 ]
Shehata, Samir [9 ]
Tawfik, Hesham [10 ]
Khorshid, Ola [11 ]
Selim, Ahmed [12 ]
Assem, Akram [13 ]
Abdelkarim, Khalid [1 ]
El-Arab, Lobna Ezz [1 ]
Bazarbashi, Shouki [14 ]
Omar, Abbass [15 ]
Elwakil, Hesham [1 ]
Elashry, Mohamed [16 ]
Abou ElFotouh, Mohamed [17 ]
Osman, Tarek [18 ]
El Din, Mai Ezz [1 ]
机构
[1] Ain Shams Univ, Fac Med, Clin Oncol Dept, Cairo, Egypt
[2] Univ Hosp Nord St Etienne, Dept Urol, St Etienne, France
[3] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44106 USA
[4] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[6] Hop Henri Mondor, Dept Urol, Creteil, France
[7] Univ Hosp Schleswig Holstein, Dept Urol & Urol Oncol, Campus Lubeck, Lubeck, Germany
[8] NHS Fdn Trust, Hampshire Hosp, Dept Urol, Basingstoke, Hants, England
[9] Assiut Univ, Clin Oncol Dept, Canc Ctr, Assiut, Egypt
[10] Tanta Univ, Clin Oncol Dept, Tanta, Egypt
[11] Cairo Univ, Natl Canc Inst, Med Oncol Dept, Cairo, Egypt
[12] Cairo Univ, Fac Med, Clin Oncol Dept, Cairo, Egypt
[13] Alexandria Univ, Urol Dept, Alexandria, Egypt
[14] King Faisal Specialist Hosp & Res Ctr, Med Oncol Dept, Riyadh, Saudi Arabia
[15] Alexandria Univ, Fac Med, Dept Clin Oncol, Alexandria, Egypt
[16] Mansoura Univ, Fac Med, Dept Clin Oncol, Mansoura, Egypt
[17] Menoufia Univ, Fac Med, Dept Clin Oncol, Al Minufya, Egypt
[18] Ain Shams Univ, Dept Urol, Cairo, Egypt
关键词
Prostate cancer; Consensus; Advanced prostate cancer; Metastatic prostate cancer; ANDROGEN-DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; OPEN-LABEL; ADJUVANT RADIOTHERAPY; PHASE-III; DOCETAXEL; DEGARELIX; ENZALUTAMIDE; MITOXANTRONE; ABIRATERONE;
D O I
10.1007/s00345-020-03328-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose Advancements in the diagnosis and treatment of prostate cancer (PC) have rapidly progressed through the past years. Various factors should be taken into account while treating individual patients to ensure optimal and careful decision making. The purpose of this consensus review is to summarize the current practice patterns when managing patients with advanced prostate cancer (APC) as there is still a lack of or very limited evidence on its clinical management in some areas. Methods Pre-defined questions were shared with experts prior to the consensus session that took place in Cairo, Egypt in April 2019 during the 8th International gastrointestinal, liver and uro-oncology conference (IGILUC). Voting was based mainly on the expert opinions of the panel after a thorough discussion and review of available evidence from guidelines or best evidence available concerning the topic at hand. Results A strong consensus or unanimity was reached on 47% of the proposed questions. Notably, the panelists reached consensus on several topics based on high-level expert opinion. These findings contribute in several ways to our understanding of the management of PC and provide a basis for future recommendations. There was also a lack of consensus on other several topics, which suggests the need for further supporting data addressing these knowledge gaps. Conclusion This review offers a thorough understanding of APC practice and offers insight on the various opinions shared amongst experts in the field that can serve as guidance regionally and deepens our understanding of disease management globally.
引用
收藏
页码:1421 / 1429
页数:9
相关论文
共 40 条
[1]   Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist [J].
Albertsen, Peter C. ;
Klotz, Laurence ;
Tombal, Bertrand ;
Grady, James ;
Olesen, Tine K. ;
Nilsson, Jan .
EUROPEAN UROLOGY, 2014, 65 (03) :565-573
[2]  
[Anonymous], 2018, ANN ONCOL S8, DOI [10.1093/annonc/mdy284, DOI 10.1093/ANN0NC/MDY284]
[3]  
[Anonymous], 2019, EAU GUIDELINES EAU E
[4]  
[Anonymous], 2019, ANN ONCOL S5, DOI DOI 10.1093/annonc/mdz394
[5]   AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].
Antonarakis, Emmanuel S. ;
Lu, Changxue ;
Wang, Hao ;
Luber, Brandon ;
Nakazawa, Mary ;
Roeser, Jeffrey C. ;
Chen, Yan ;
Mohammad, Tabrez A. ;
Chen, Yidong ;
Fedor, Helen L. ;
Lotan, Tamara L. ;
Zheng, Qizhi ;
De Marzo, Angelo M. ;
Isaacs, John T. ;
Isaacs, William B. ;
Nadal, Rosa ;
Paller, Channing J. ;
Denmeade, Samuel R. ;
Carducci, Michael A. ;
Eisenberger, Mario A. ;
Luo, Jun .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038
[6]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[7]   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].
Berthold, Dominik R. ;
Pond, Gregory R. ;
Soban, Freidele ;
de Wit, Ronald ;
Eisenberger, Mario ;
Tannock, Ian F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245
[8]  
Boevé LMS, 2019, EUR UROL, V75, P410, DOI 10.1016/j.eururo.2018.09.008
[9]   Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) [J].
Bolla, Michel ;
van Poppel, Hein ;
Tombal, Bertrand ;
Vekemans, Kris ;
Da Pozzo, Luigi ;
de Reijke, Theo M. ;
Verbaeys, Antony ;
Bosset, Jean-Francois ;
van Velthoven, Roland ;
Colombel, Marc ;
van de Beek, Cees ;
Verhagen, Paul ;
van den Bergh, Alphonsus ;
Sternberg, Cora ;
Gasser, Thomas ;
van Tienhoven, Geertjan ;
Scalliet, Pierre ;
Haustermans, Karin ;
Collette, Laurence .
LANCET, 2012, 380 (9858) :2018-2027
[10]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]